董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Batycky | 男 | Director | 58 | 5.40万美元 | 0.55 | 2026-06-30 |
| Michael J. Higgins | 男 | Chairman of the Board and Director | 63 | 8.50万美元 | 0.88 | 2026-06-30 |
| Anand Varadan | 男 | Director | 59 | 4.00万美元 | 0.42 | 2026-06-30 |
| Todd Bazemore | 男 | Director | 55 | 5.25万美元 | 0.50 | 2026-06-30 |
| Christopher Cabell | 男 | Director | 57 | 4.50万美元 | 0.50 | 2026-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Ludlum | 男 | Interim Chief Executive Officer and Interim Chief Financial Officer | 70 | 71.52万美元 | 未持股 | 2026-06-30 |
董事简历
中英对照 | 中文 | 英文- Richard Batycky
-
Richard Batycky博士是Civitas Therapeutics，Inc.的创始成员，自2010年12月起担任Civitas Therapeutics, Inc.首席科学官。Batycky博士还于2009年10月至2011年10月担任Aura Biosciences公司药物开发副总裁。在加入Civitas Therapeutics, Inc.之前，Batycky博士曾于2007年5月至2009年2月在Pulmatrix公司担任首席科学官和研发高级副总裁。Pulmatrix公司是一家私人临床阶段制药公司，致力于开发治疗和预防呼吸系统疾病的新疗法。在Pulmatrix, Inc.，Batycky博士领导了产品开发的各个方面，用于治疗、预防和抗各种呼吸道疾病中的病毒和细菌病原体的传染。在加入Pulmatrix, Inc.之前，Batycky博士曾于1999年2月至2001年9月担任阿尔凯默斯的董事，该公司是一家拥有多个成功产品的生物制药公司，2001年9月至2007年5月担任研发副总裁。在Alkermes工作期间，Batycky博士负责产品开发的许多方面，包括吸入式治疗平台，现在是Civitas Therapeutics, Inc.公司的ARCUS技术。他在不同阶段参与了10多个候选产品的开发，这些候选产品包括专利和跨多个递送平台（肺部、注射和口服）的合作伙伴。在加入Alkermes之前，Batycky博士于1998年1月至1999年2月担任AIR总监，直到被Alkermes收购。在加入AIR之前，Batycky博士是阿尔伯塔大学化学工程助理教授和宾夕法尼亚州立大学博士后研究员。Batycky博士在卡尔加里大学获得学士学位，在麻省理工学院获得化学工程硕士和博士学位。
Richard Batycky was appointed to serve as a director of Pulmatrix in November 2019. He is currently the President and Chief Executive Officer of Nocion Therapeutics, Inc. having served in such position since 2018. Dr. Batycky has over two decades of experience with biotech start ups from founding to acquisition across an array of platforms and disease states with notable expertise in inhaled drug development. From 2009 to 2014, he was the Chief Scientific Officer and a founder of Civitas Therapeutics, which was acquired by Acorda Therapeutics, Inc., or Acorda. At Acorda, he served as Chief Technology Officer from 2014 to 2018 where he led its novel dry powder inhalation therapy to treat motor issues in Parkinson's patients through to FDA approval as Inbrija. Prior to Civitas Therapeutics, he was Chief Scientific Officer and Senior VP of R&D at Pulmatrix from 2007 to 2009 and held prior positions at Alkermes and Advanced Inhalation Research from 1998 to 2007. Dr. Batycky received his B.Sc. in Chemical Engineering from the University of Calgary and his S.M. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT). - Richard Batycky博士是Civitas Therapeutics，Inc.的创始成员，自2010年12月起担任Civitas Therapeutics, Inc.首席科学官。Batycky博士还于2009年10月至2011年10月担任Aura Biosciences公司药物开发副总裁。在加入Civitas Therapeutics, Inc.之前，Batycky博士曾于2007年5月至2009年2月在Pulmatrix公司担任首席科学官和研发高级副总裁。Pulmatrix公司是一家私人临床阶段制药公司，致力于开发治疗和预防呼吸系统疾病的新疗法。在Pulmatrix, Inc.，Batycky博士领导了产品开发的各个方面，用于治疗、预防和抗各种呼吸道疾病中的病毒和细菌病原体的传染。在加入Pulmatrix, Inc.之前，Batycky博士曾于1999年2月至2001年9月担任阿尔凯默斯的董事，该公司是一家拥有多个成功产品的生物制药公司，2001年9月至2007年5月担任研发副总裁。在Alkermes工作期间，Batycky博士负责产品开发的许多方面，包括吸入式治疗平台，现在是Civitas Therapeutics, Inc.公司的ARCUS技术。他在不同阶段参与了10多个候选产品的开发，这些候选产品包括专利和跨多个递送平台（肺部、注射和口服）的合作伙伴。在加入Alkermes之前，Batycky博士于1998年1月至1999年2月担任AIR总监，直到被Alkermes收购。在加入AIR之前，Batycky博士是阿尔伯塔大学化学工程助理教授和宾夕法尼亚州立大学博士后研究员。Batycky博士在卡尔加里大学获得学士学位，在麻省理工学院获得化学工程硕士和博士学位。
- Richard Batycky was appointed to serve as a director of Pulmatrix in November 2019. He is currently the President and Chief Executive Officer of Nocion Therapeutics, Inc. having served in such position since 2018. Dr. Batycky has over two decades of experience with biotech start ups from founding to acquisition across an array of platforms and disease states with notable expertise in inhaled drug development. From 2009 to 2014, he was the Chief Scientific Officer and a founder of Civitas Therapeutics, which was acquired by Acorda Therapeutics, Inc., or Acorda. At Acorda, he served as Chief Technology Officer from 2014 to 2018 where he led its novel dry powder inhalation therapy to treat motor issues in Parkinson's patients through to FDA approval as Inbrija. Prior to Civitas Therapeutics, he was Chief Scientific Officer and Senior VP of R&D at Pulmatrix from 2007 to 2009 and held prior positions at Alkermes and Advanced Inhalation Research from 1998 to 2007. Dr. Batycky received his B.Sc. in Chemical Engineering from the University of Calgary and his S.M. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).
- Michael J. Higgins
-
Michael J. Higgins于2020年4月被任命为董事会主席。自2015年6月起担任董事会成员。他自2019年6月起担任上市生物制药公司Voyager Therapeutics的董事会主席，并于2021年6月至2022年3月担任Voyager的临时首席执行官。他曾于2015年至2022年6月担任上市免疫肿瘤公司Genocea Biosciences公司的董事会成员；自2020年9月起担任生物制药公司Nocion Therapeutics，Inc.；自2017年10月起担任生物制药公司Camp4 Therapeutics Corporation；自2016年3月至2020年3月担任生物技术公司KinDex Pharmaceuticals，Inc.的董事会成员。Higgins是一位连续创业者，在他的职业生涯中帮助创办/建立了许多公司。2015年至2020年，他在投资公司Polaris Partners担任驻场企业家。2003年至2014年，他在生物制药公司Ironwood医药公司担任高级副总裁兼首席运营官。在2003年之前，Higgins先生曾在Genzyme Corporation担任多个高级业务职位，包括公司财务副总裁和业务发展副总裁。在加入Genzyme Corporation之前，Higgins先生领导Procept公司的财务团队，从创立到首次公开发行。希金斯在Cornell University获得了学士学位，在Dartmouth College的Amos Tuck School of Business获得了工商管理硕士学位。
Michael J. Higgins was appointed Chairman of the Pulmatrix board of directors in April 2020. He has been a member of the Pulmatrix board of directors since June 2015. He has served as chairman of the board of directors of Voyager Therapeutics, a publicly traded biopharmaceutical company, since June 2019, and served as Voyager's Interim CEO from June 2021 through March 2022. He has served as a board member of Genocea Biosciences Inc., a publicly traded immuno oncology company, from 2015 to June 2022; Nocion Therapeutics, Inc., a biopharmaceutical company, since September 2020; Camp4 Therapeutics Corporation, a biopharmaceutical company, since October 2017 and Cyclerion Therapeutics, Inc., a publicly traded biopharmaceutical company, since November 2023. Mr. Higgins is a serial entrepreneur who has helped launch/build numerous companies during his career. He served as Entrepreneur in Residence at Polaris Partners, an investment company, from 2015 to 2020. From 2003 to 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc, a biopharmaceutical company. Prior to 2003, Mr. Higgins held a variety of senior business positions at Genzyme Corporation, including Vice President of Corporate Finance and Vice President of Business Development. Prior to joining Genzyme Corporation, Mr. Higgins led Procept, Inc.'s financial team from founding through its initial public offering. Mr. Higgins earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College. - Michael J. Higgins于2020年4月被任命为董事会主席。自2015年6月起担任董事会成员。他自2019年6月起担任上市生物制药公司Voyager Therapeutics的董事会主席，并于2021年6月至2022年3月担任Voyager的临时首席执行官。他曾于2015年至2022年6月担任上市免疫肿瘤公司Genocea Biosciences公司的董事会成员；自2020年9月起担任生物制药公司Nocion Therapeutics，Inc.；自2017年10月起担任生物制药公司Camp4 Therapeutics Corporation；自2016年3月至2020年3月担任生物技术公司KinDex Pharmaceuticals，Inc.的董事会成员。Higgins是一位连续创业者，在他的职业生涯中帮助创办/建立了许多公司。2015年至2020年，他在投资公司Polaris Partners担任驻场企业家。2003年至2014年，他在生物制药公司Ironwood医药公司担任高级副总裁兼首席运营官。在2003年之前，Higgins先生曾在Genzyme Corporation担任多个高级业务职位，包括公司财务副总裁和业务发展副总裁。在加入Genzyme Corporation之前，Higgins先生领导Procept公司的财务团队，从创立到首次公开发行。希金斯在Cornell University获得了学士学位，在Dartmouth College的Amos Tuck School of Business获得了工商管理硕士学位。
- Michael J. Higgins was appointed Chairman of the Pulmatrix board of directors in April 2020. He has been a member of the Pulmatrix board of directors since June 2015. He has served as chairman of the board of directors of Voyager Therapeutics, a publicly traded biopharmaceutical company, since June 2019, and served as Voyager's Interim CEO from June 2021 through March 2022. He has served as a board member of Genocea Biosciences Inc., a publicly traded immuno oncology company, from 2015 to June 2022; Nocion Therapeutics, Inc., a biopharmaceutical company, since September 2020; Camp4 Therapeutics Corporation, a biopharmaceutical company, since October 2017 and Cyclerion Therapeutics, Inc., a publicly traded biopharmaceutical company, since November 2023. Mr. Higgins is a serial entrepreneur who has helped launch/build numerous companies during his career. He served as Entrepreneur in Residence at Polaris Partners, an investment company, from 2015 to 2020. From 2003 to 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc, a biopharmaceutical company. Prior to 2003, Mr. Higgins held a variety of senior business positions at Genzyme Corporation, including Vice President of Corporate Finance and Vice President of Business Development. Prior to joining Genzyme Corporation, Mr. Higgins led Procept, Inc.'s financial team from founding through its initial public offering. Mr. Higgins earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College.
- Anand Varadan
-
Anand Varadan加入Chiasma, Inc. （Chiasma, Inc.)。2020年4月担任执行副总裁兼首席商务官，此前曾担任Chiasma, Inc.。2015年8月至2016年6月担任首席商务官。最近，Varadan先生通过他的咨询公司Ignition Insights, LLC（自2016年6月起运营）向公司以及各种其他生物技术公司和投资者提供商业和战略咨询服务。从2018年6月到2019年7月，Varadan先生担任Karyopharm Therapeutics, Inc.的执行副总裁兼首席商务官。纳斯达克：KPTI，一家专注于肿瘤学的制药公司。1999年1月至2015年7月，他在生物制药公司Amgen Inc.（纳斯达克股票代码：AMGN）担任商业领导和一般管理职务，包括2014年4月至2015年7月担任炎症和肾脏病业务部副总裁，2011年9月至2014年4月担任Amgen Canada副总裁/总经理。加入Amgen之前，他是Procter and Gamble Company （NYSE： PG）的品牌经理。Varadan先生拥有George Washington大学的学士学位和Rochester大学Simon商学院的工商管理硕士学位。
Anand Varadan was appointed to serve as a director of Pulmatrix in July 2021. He is currently the founder and President of Ignition Insights, LLC, a consulting firm providing commercial and strategic consultancy services to biopharma companies and investors. Previously, he was Executive Vice President, Chief Commercial Officer at Chiasma Inc., a commercial stage biopharmaceutical company, until its acquisition by Amryt PLC. Mr. Varadan also served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics, Inc, an oncology focused pharmaceutical company, where he started up commercial operations leading to the successful launch of XPOVIO for multiple myeloma. Earlier in his career, Mr. Varadan held executive leadership roles at Amgen Inc., a biopharmaceutical company, in the United States, European Union, and Canada including Vice President, U.S. Inflammation and Nephrology Business Unit and Vice President and General Manager, Amgen Canada. Prior to Amgen, Mr. Varadan was a brand manager at Procter and Gamble Company. Mr. Varadan has a B.A. from George Washington University and an M.B.A. from the Simon Business School at the University of Rochester. - Anand Varadan加入Chiasma, Inc. （Chiasma, Inc.)。2020年4月担任执行副总裁兼首席商务官，此前曾担任Chiasma, Inc.。2015年8月至2016年6月担任首席商务官。最近，Varadan先生通过他的咨询公司Ignition Insights, LLC（自2016年6月起运营）向公司以及各种其他生物技术公司和投资者提供商业和战略咨询服务。从2018年6月到2019年7月，Varadan先生担任Karyopharm Therapeutics, Inc.的执行副总裁兼首席商务官。纳斯达克：KPTI，一家专注于肿瘤学的制药公司。1999年1月至2015年7月，他在生物制药公司Amgen Inc.（纳斯达克股票代码：AMGN）担任商业领导和一般管理职务，包括2014年4月至2015年7月担任炎症和肾脏病业务部副总裁，2011年9月至2014年4月担任Amgen Canada副总裁/总经理。加入Amgen之前，他是Procter and Gamble Company （NYSE： PG）的品牌经理。Varadan先生拥有George Washington大学的学士学位和Rochester大学Simon商学院的工商管理硕士学位。
- Anand Varadan was appointed to serve as a director of Pulmatrix in July 2021. He is currently the founder and President of Ignition Insights, LLC, a consulting firm providing commercial and strategic consultancy services to biopharma companies and investors. Previously, he was Executive Vice President, Chief Commercial Officer at Chiasma Inc., a commercial stage biopharmaceutical company, until its acquisition by Amryt PLC. Mr. Varadan also served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics, Inc, an oncology focused pharmaceutical company, where he started up commercial operations leading to the successful launch of XPOVIO for multiple myeloma. Earlier in his career, Mr. Varadan held executive leadership roles at Amgen Inc., a biopharmaceutical company, in the United States, European Union, and Canada including Vice President, U.S. Inflammation and Nephrology Business Unit and Vice President and General Manager, Amgen Canada. Prior to Amgen, Mr. Varadan was a brand manager at Procter and Gamble Company. Mr. Varadan has a B.A. from George Washington University and an M.B.A. from the Simon Business School at the University of Rochester.
- Todd Bazemore
-
2020年10月，Todd Bazemore被任命为Pulmatrix, Inc.公司董事。Todd Bazemore自2021年12月起担任Kala制药公司总裁兼首席运营官，并于2017年11月至2021年11月担任首席运营官。此前，他曾于2016年9月至2017年11月担任Santhera Pharmaceuticals（USA）Inc.执行副总裁兼首席运营官，该公司是一家制药公司，是Santhera Pharmaceuticals Holdings AG的子公司。在加入Santhera之前，Bazemore先生曾在2014年4月至2016年1月期间担任Dyax Corp.的执行副总裁兼首席商务官，该公司是一家专注于孤儿疾病的生物制药公司，德纳维制药被Shire plc收购。2012年4月至2013年9月期间，他在Sunovion Pharmaceuticals，Inc.，或Sunovion（大日本住友制药有限公司的子公司）担任管理市场副总裁，这是一家专注于严重疾病的全球性生物制药公司。在此之前，Bazemore先生在Sunovion担任过几个职责日益增加的职位，包括销售副总裁和呼吸业务部门副总裁。他在马萨诸塞大学洛厄尔分校获得理学学士学位。
Todd Bazemore was appointed to serve as a director of Pulmatrix in October 2020. Todd Bazemore has been the President and CEO of AIRNA since June 2026. Before AIRNA, he was the CEO and director at KALA BIO, Inc., which he joined in November 2021, and where he also served as the President and Chief Operating Officer since December 2021 and as the Chief Operating Officer from November 2017 through November 2021. Previously, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc., or Santhera, a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp., or Dyax, a biopharmaceutical company focused on orphan diseases, between April 2014 and January 2016, when Dyax was acquired by Shire plc. Between April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc., or Sunovion (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of the Respiratory Business Unit. He received his Bachelor of Science from the University of Massachusetts, Lowell. - 2020年10月，Todd Bazemore被任命为Pulmatrix, Inc.公司董事。Todd Bazemore自2021年12月起担任Kala制药公司总裁兼首席运营官，并于2017年11月至2021年11月担任首席运营官。此前，他曾于2016年9月至2017年11月担任Santhera Pharmaceuticals（USA）Inc.执行副总裁兼首席运营官，该公司是一家制药公司，是Santhera Pharmaceuticals Holdings AG的子公司。在加入Santhera之前，Bazemore先生曾在2014年4月至2016年1月期间担任Dyax Corp.的执行副总裁兼首席商务官，该公司是一家专注于孤儿疾病的生物制药公司，德纳维制药被Shire plc收购。2012年4月至2013年9月期间，他在Sunovion Pharmaceuticals，Inc.，或Sunovion（大日本住友制药有限公司的子公司）担任管理市场副总裁，这是一家专注于严重疾病的全球性生物制药公司。在此之前，Bazemore先生在Sunovion担任过几个职责日益增加的职位，包括销售副总裁和呼吸业务部门副总裁。他在马萨诸塞大学洛厄尔分校获得理学学士学位。
- Todd Bazemore was appointed to serve as a director of Pulmatrix in October 2020. Todd Bazemore has been the President and CEO of AIRNA since June 2026. Before AIRNA, he was the CEO and director at KALA BIO, Inc., which he joined in November 2021, and where he also served as the President and Chief Operating Officer since December 2021 and as the Chief Operating Officer from November 2017 through November 2021. Previously, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc., or Santhera, a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp., or Dyax, a biopharmaceutical company focused on orphan diseases, between April 2014 and January 2016, when Dyax was acquired by Shire plc. Between April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc., or Sunovion (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of the Respiratory Business Unit. He received his Bachelor of Science from the University of Massachusetts, Lowell.
- Christopher Cabell
-
2020年6月，克里斯托弗·卡贝尔被任命为Pulmatrix, Inc.公司董事。他目前是Zura Bio有限公司的首席医疗官和执行副总裁，于2023年1月加入。在加入Zura Bio之前，Cabell博士是Emergent BioSolutions，Inc.的首席医疗官和临床开发主管，于2021年2月加入。此前，卡贝尔博士在阿里那制药公司工作了三（3）年，从2017年10月到2020年11月，他的职责越来越多，包括研发主管和首席医疗官。2007年10月至2017年9月，卡贝尔博士在昆泰公司和QuintilesIMS工作了10年，担任过多个管理职位，包括首席医疗和科学官、全球医疗和项目管理主管，以及全球业务发展主管。在加入昆泰之前，卡贝尔博士是杜克大学医学院心脏病学部的教员。卡贝尔博士是美国心脏病学会院士，在《新英格兰医学杂志》、《美国医学会杂志》和《内科学年鉴》等杂志上发表了100多篇同行评议的文章。Cabell博士是宾夕法尼亚州立大学和杜克大学的荣誉毕业生，同时获得医学学位和Health Sciences硕士学位。
Christopher Cabell was appointed to serve as a director of Pulmatrix in June 2020. He is currently the President and Head of Research & Development at Inhibikase Therapeutics. Prior to joining Inhibikase Therapeutics in February 2025, Dr. Cabell was Chief Executive Officer at CorHepta Pharmaceuticals. Previously, Dr. Cabell was Chief Medical Officer at Arena Pharmaceuticals, Zura Bio and Emergent BioSolutions. Dr. Cabell has also served on multiple corporate and scientific advisory boards. Earlier in his career, Dr. Cabell was a consultant, founding HD Consulting and serving as Head of the Therapeutic & Specialty Business Development team for Quintiles. Dr. Cabell was on faculty at Duke University School of Medicine in the Division of Cardiology. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is an honors graduate of Pennsylvania State University and Duke University, earning both his Medical Degree and a Masters in Health Sciences from the latter. - 2020年6月，克里斯托弗·卡贝尔被任命为Pulmatrix, Inc.公司董事。他目前是Zura Bio有限公司的首席医疗官和执行副总裁，于2023年1月加入。在加入Zura Bio之前，Cabell博士是Emergent BioSolutions，Inc.的首席医疗官和临床开发主管，于2021年2月加入。此前，卡贝尔博士在阿里那制药公司工作了三（3）年，从2017年10月到2020年11月，他的职责越来越多，包括研发主管和首席医疗官。2007年10月至2017年9月，卡贝尔博士在昆泰公司和QuintilesIMS工作了10年，担任过多个管理职位，包括首席医疗和科学官、全球医疗和项目管理主管，以及全球业务发展主管。在加入昆泰之前，卡贝尔博士是杜克大学医学院心脏病学部的教员。卡贝尔博士是美国心脏病学会院士，在《新英格兰医学杂志》、《美国医学会杂志》和《内科学年鉴》等杂志上发表了100多篇同行评议的文章。Cabell博士是宾夕法尼亚州立大学和杜克大学的荣誉毕业生，同时获得医学学位和Health Sciences硕士学位。
- Christopher Cabell was appointed to serve as a director of Pulmatrix in June 2020. He is currently the President and Head of Research & Development at Inhibikase Therapeutics. Prior to joining Inhibikase Therapeutics in February 2025, Dr. Cabell was Chief Executive Officer at CorHepta Pharmaceuticals. Previously, Dr. Cabell was Chief Medical Officer at Arena Pharmaceuticals, Zura Bio and Emergent BioSolutions. Dr. Cabell has also served on multiple corporate and scientific advisory boards. Earlier in his career, Dr. Cabell was a consultant, founding HD Consulting and serving as Head of the Therapeutic & Specialty Business Development team for Quintiles. Dr. Cabell was on faculty at Duke University School of Medicine in the Division of Cardiology. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is an honors graduate of Pennsylvania State University and Duke University, earning both his Medical Degree and a Masters in Health Sciences from the latter.
高管简历
中英对照 | 中文 | 英文- Peter Ludlum
Peter Ludlum于2012年4月2日正式被任命为公司执行副总裁和首席财务官。Ludlum之前从208年4月到2012年3月担任Energy and Power Solutions, Inc. 首席财务官。Ludlum从2006年4月到2008年3月担任Applied Medical Resources Corporation金融合规官；2005年4月到2006年4月担任首席财务官。Ludlum还从2003年10月到2005年4月担任IsoTis S.A.集团总监。IsoTis S.A.于2003年10月收购GenSci Regeneration Sciences Inc.，Ludlum从1999年12月到2003年10月担任副总裁和首席财务官。加入GenSci之前，Ludlum从1996年11月到1999年12月担任Pacific Biometrics, Inc.金融副总裁和首席财务官。在他的职业生涯早期，Ludlum曾在Derlan Industries, Ltd.担任企业总监和财务主管；在Mobil Oil Corporation及其附属公司Bechtel Corporation and PacifiCorp担任多个职位。Ludlum是一名注册管理会计师CMA。他于1977年获得Lehigh University商业和经济学理学学士学位，主修会计；1991年获得富勒顿California State University工商管理硕士学位，主修金融。
Peter Ludlum has served as Pulmatrix's interim Chief Executive Officer and principal executive officer since July 20, 2024, its interim Chief Financial Officer, principal accounting officer and principal financial officer since April 2022, and its Strategic Advisor Finance since December 2021, all pursuant to a November 30, 2021, consulting agreement and subsequent amendments thereto, by and between Pulmatrix and Danforth Advisors, LLC ("Danforth"). Mr. Ludlum has served as an employee with Danforth, a provider of strategic and operational finance and accounting for life science companies, since December 2021. Prior to Danforth, Mr. Ludlum worked as an independent financial consultant. Previously, Mr. Ludlum served in several executive roles at Emmaus Life Sciences, Inc. (n/k/a EMI Holding, Inc.), a commercial stage biopharmaceutical company, including Co President, Chief Business Officer, Executive Vice President and Chief Financial Officer, during his tenure from April 2012 until May 2017. Mr. Ludlum previously served as the Chief Financial Officer of Energy and Power Solutions, Inc., an energy intelligence company, from April 2008 to December 2011. He received a B.S. in Business and Economics with a major in accounting from Lehigh University and an MBA with a concentration in Finance from California State University, Fullerton.- Peter Ludlum于2012年4月2日正式被任命为公司执行副总裁和首席财务官。Ludlum之前从208年4月到2012年3月担任Energy and Power Solutions, Inc. 首席财务官。Ludlum从2006年4月到2008年3月担任Applied Medical Resources Corporation金融合规官；2005年4月到2006年4月担任首席财务官。Ludlum还从2003年10月到2005年4月担任IsoTis S.A.集团总监。IsoTis S.A.于2003年10月收购GenSci Regeneration Sciences Inc.，Ludlum从1999年12月到2003年10月担任副总裁和首席财务官。加入GenSci之前，Ludlum从1996年11月到1999年12月担任Pacific Biometrics, Inc.金融副总裁和首席财务官。在他的职业生涯早期，Ludlum曾在Derlan Industries, Ltd.担任企业总监和财务主管；在Mobil Oil Corporation及其附属公司Bechtel Corporation and PacifiCorp担任多个职位。Ludlum是一名注册管理会计师CMA。他于1977年获得Lehigh University商业和经济学理学学士学位，主修会计；1991年获得富勒顿California State University工商管理硕士学位，主修金融。
- Peter Ludlum has served as Pulmatrix's interim Chief Executive Officer and principal executive officer since July 20, 2024, its interim Chief Financial Officer, principal accounting officer and principal financial officer since April 2022, and its Strategic Advisor Finance since December 2021, all pursuant to a November 30, 2021, consulting agreement and subsequent amendments thereto, by and between Pulmatrix and Danforth Advisors, LLC ("Danforth"). Mr. Ludlum has served as an employee with Danforth, a provider of strategic and operational finance and accounting for life science companies, since December 2021. Prior to Danforth, Mr. Ludlum worked as an independent financial consultant. Previously, Mr. Ludlum served in several executive roles at Emmaus Life Sciences, Inc. (n/k/a EMI Holding, Inc.), a commercial stage biopharmaceutical company, including Co President, Chief Business Officer, Executive Vice President and Chief Financial Officer, during his tenure from April 2012 until May 2017. Mr. Ludlum previously served as the Chief Financial Officer of Energy and Power Solutions, Inc., an energy intelligence company, from April 2008 to December 2011. He received a B.S. in Business and Economics with a major in accounting from Lehigh University and an MBA with a concentration in Finance from California State University, Fullerton.